Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastoma.

Eckerdt F, Clymer J, Bell JB, Beauchamp EM, Blyth GT, Goldman S, Platanias LC.

Sci Rep. 2019 Sep 6;9(1):12822. doi: 10.1038/s41598-019-49299-3.

2.

Discovery of novel Mnk inhibitors using mutation-based induced-fit virtual high-throughput screening.

Mishra RK, Clutter MR, Blyth GT, Kosciuczuk EM, Blackburn AZ, Beauchamp EM, Schiltz GE, Platanias LC.

Chem Biol Drug Des. 2019 Oct;94(4):1813-1823. doi: 10.1111/cbdd.13585. Epub 2019 Aug 4.

PMID:
31260185
3.

Potent Antineoplastic Effects of Combined PI3Kα-MNK Inhibition in Medulloblastoma.

Eckerdt F, Bell JB, Beauchamp EM, Clymer J, Blyth GT, Kosciuczuk EM, Ma Q, Chen DZ, Horbinski C, Goldman S, Munshi HG, Hashizume R, Platanias LC.

Mol Cancer Res. 2019 Jun;17(6):1305-1315. doi: 10.1158/1541-7786.MCR-18-1193. Epub 2019 Mar 6.

PMID:
30842251
4.

Identification and targeting of novel CDK9 complexes in acute myeloid leukemia.

Beauchamp EM, Abedin SM, Radecki SG, Fischietti M, Arslan AD, Blyth GT, Yang A, Lantz C, Nelson A, Goo YA, Akpan I, Eklund EA, Frankfurt O, Fish EN, Thomas PM, Altman JK, Platanias LC.

Blood. 2019 Mar 14;133(11):1171-1185. doi: 10.1182/blood-2018-08-870089. Epub 2018 Dec 26.

PMID:
30587525
5.

Identification and characterization of an alternative cancer-derived PD-L1 splice variant.

Hassounah NB, Malladi VS, Huang Y, Freeman SS, Beauchamp EM, Koyama S, Souders N, Martin S, Dranoff G, Wong KK, Pedamallu CS, Hammerman PS, Akbay EA.

Cancer Immunol Immunother. 2019 Mar;68(3):407-420. doi: 10.1007/s00262-018-2284-z. Epub 2018 Dec 18.

PMID:
30564890
6.

Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation.

Bell JB, Eckerdt F, Dhruv HD, Finlay D, Peng S, Kim S, Kroczynska B, Beauchamp EM, Alley K, Clymer J, Goldman S, Cheng SY, James CD, Nakano I, Horbinski C, Mazar AP, Vuori K, Kumthekar P, Raizer J, Berens ME, Platanias LC.

Mol Cancer Res. 2018 Jan;16(1):32-46. doi: 10.1158/1541-7786.MCR-17-0397. Epub 2017 Oct 17.

7.

Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo.

Kosciuczuk EM, Saleiro D, Kroczynska B, Beauchamp EM, Eckerdt F, Blyth GT, Abedin SM, Giles FJ, Altman JK, Platanias LC.

Blood. 2016 Jul 21;128(3):410-4. doi: 10.1182/blood-2016-02-698704. Epub 2016 Jun 15.

8.

Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer.

Terai H, Tan L, Beauchamp EM, Hatcher JM, Liu Q, Meyerson M, Gray NS, Hammerman PS.

ACS Chem Biol. 2015 Dec 18;10(12):2687-96. doi: 10.1021/acschembio.5b00655. Epub 2015 Sep 25.

9.

Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias.

Curi DA, Beauchamp EM, Blyth GT, Arslan AD, Donato NJ, Giles FJ, Altman JK, Platanias LC.

Oncotarget. 2015 Oct 20;6(32):33206-16. doi: 10.18632/oncotarget.5091.

10.

NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy.

Xu C, Buczkowski KA, Zhang Y, Asahina H, Beauchamp EM, Terai H, Li YY, Meyerson M, Wong KK, Hammerman PS.

Mol Cancer Ther. 2015 Oct;14(10):2382-2389. doi: 10.1158/1535-7163.MCT-15-0077. Epub 2015 Jul 23.

11.

Human Schlafen 5 (SLFN5) Is a Regulator of Motility and Invasiveness of Renal Cell Carcinoma Cells.

Sassano A, Mavrommatis E, Arslan AD, Kroczynska B, Beauchamp EM, Khuon S, Chew TL, Green KJ, Munshi HG, Verma AK, Platanias LC.

Mol Cell Biol. 2015 Aug;35(15):2684-98. doi: 10.1128/MCB.00019-15. Epub 2015 May 26.

12.

Central role of ULK1 in type I interferon signaling.

Saleiro D, Mehrotra S, Kroczynska B, Beauchamp EM, Lisowski P, Majchrzak-Kita B, Bhagat TD, Stein BL, McMahon B, Altman JK, Kosciuczuk EM, Baker DP, Jie C, Jafari N, Thompson CB, Levine RL, Fish EN, Verma AK, Platanias LC.

Cell Rep. 2015 Apr 28;11(4):605-17. doi: 10.1016/j.celrep.2015.03.056. Epub 2015 Apr 16.

13.

Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase.

Colamonici M, Blyth G, Saleiro D, Szilard A, Bliss-Moreau M, Giles FJ, Altman JK, Beauchamp EM, Platanias LC.

Oncotarget. 2015 Apr 10;6(10):8062-70.

14.

Direct binding of arsenic trioxide to AMPK and generation of inhibitory effects on acute myeloid leukemia precursors.

Beauchamp EM, Kosciuczuk EM, Serrano R, Nanavati D, Swindell EP, Viollet B, O'Halloran TV, Altman JK, Platanias LC.

Mol Cancer Ther. 2015 Jan;14(1):202-12. doi: 10.1158/1535-7163.MCT-14-0665-T. Epub 2014 Oct 24.

15.

Overcoming treatment challenges in imatinib-resistant chronic myelogenous leukemia.

Curi DA, Beauchamp EM, Platanias LC.

Leuk Lymphoma. 2015 Jun;56(6):1581-2. doi: 10.3109/10428194.2014.970549. Epub 2014 Nov 5. No abstract available.

PMID:
25284498
16.

The Prochlorococcus carbon dioxide-concentrating mechanism: evidence of carboxysome-associated heterogeneity.

Ting CS, Dusenbury KH, Pryzant RA, Higgins KW, Pang CJ, Black CE, Beauchamp EM.

Photosynth Res. 2015 Jan;123(1):45-60. doi: 10.1007/s11120-014-0038-0. Epub 2014 Sep 6.

PMID:
25193505
17.

Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting.

Altman JK, Szilard A, Goussetis DJ, Sassano A, Colamonici M, Gounaris E, Frankfurt O, Giles FJ, Eklund EA, Beauchamp EM, Platanias LC.

Clin Cancer Res. 2014 May 1;20(9):2400-9. doi: 10.1158/1078-0432.CCR-13-3218. Epub 2014 Mar 7.

18.

Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss.

Beauchamp EM, Woods BA, Dulak AM, Tan L, Xu C, Gray NS, Bass AJ, Wong KK, Meyerson M, Hammerman PS.

Mol Cancer Ther. 2014 Feb;13(2):475-82. doi: 10.1158/1535-7163.MCT-13-0817. Epub 2013 Dec 2.

19.

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, Wilkerson MD, Fecci PE, Butaney M, Reibel JB, Soucheray M, Cohoon TJ, Janne PA, Meyerson M, Hayes DN, Shapiro GI, Shimamura T, Sholl LM, Rodig SJ, Freeman GJ, Hammerman PS, Dranoff G, Wong KK.

Cancer Discov. 2013 Dec;3(12):1355-63. doi: 10.1158/2159-8290.CD-13-0310. Epub 2013 Sep 27.

20.

Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.

Liao RG, Jung J, Tchaicha J, Wilkerson MD, Sivachenko A, Beauchamp EM, Liu Q, Pugh TJ, Pedamallu CS, Hayes DN, Gray NS, Getz G, Wong KK, Haddad RI, Meyerson M, Hammerman PS.

Cancer Res. 2013 Aug 15;73(16):5195-205. doi: 10.1158/0008-5472.CAN-12-3950. Epub 2013 Jun 20.

21.

The evolution of the TOR pathway and its role in cancer.

Beauchamp EM, Platanias LC.

Oncogene. 2013 Aug 22;32(34):3923-32. doi: 10.1038/onc.2012.567. Epub 2012 Dec 17. Review.

PMID:
23246968
22.

BH3 mimetics and multi-kinase inhibition in AML.

Beauchamp EM, Platanias LC.

Blood. 2012 Jun 21;119(25):5947-8. doi: 10.1182/blood-2012-04-420786.

PMID:
22730522
23.

A new era for an ancient drug: arsenic trioxide and Hedgehog signaling.

Beauchamp EM, Uren A.

Vitam Horm. 2012;88:333-54. doi: 10.1016/B978-0-12-394622-5.00015-8. Review.

PMID:
22391311
24.

Beta-catenin accelerates human papilloma virus type-16 mediated cervical carcinogenesis in transgenic mice.

Bulut G, Fallen S, Beauchamp EM, Drebing LE, Sun J, Berry DL, Kallakury B, Crum CP, Toretsky JA, Schlegel R, Üren A.

PLoS One. 2011;6(11):e27243. doi: 10.1371/journal.pone.0027243. Epub 2011 Nov 7.

25.

Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells.

Bulut G, Hong SH, Chen K, Beauchamp EM, Rahim S, Kosturko GW, Glasgow E, Dakshanamurthy S, Lee HS, Daar I, Toretsky JA, Khanna C, Uren A.

Oncogene. 2012 Jan 19;31(3):269-81. doi: 10.1038/onc.2011.245. Epub 2011 Jun 27.

26.

YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion.

Rahim S, Beauchamp EM, Kong Y, Brown ML, Toretsky JA, Üren A.

PLoS One. 2011 Apr 29;6(4):e19343. doi: 10.1371/journal.pone.0019343.

27.

Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway.

Beauchamp EM, Ringer L, Bulut G, Sajwan KP, Hall MD, Lee YC, Peaceman D, Ozdemirli M, Rodriguez O, Macdonald TJ, Albanese C, Toretsky JA, Uren A.

J Clin Invest. 2011 Jan;121(1):148-60. doi: 10.1172/JCI42874. Epub 2010 Dec 22.

Supplemental Content

Loading ...
Support Center